Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials

Ilo E. Leppik, Robert T. Wechsler, Betsy Williams, Haichen Yang, Sharon Zhou, Antonio Laurenza

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Clinical data regarding use of antiepileptic drugs in the elderly are generally scarce. Therefore, a subanalysis of subjects aged ≥65 years who participated in the 3 phase III perampanel studies was undertaken to determine efficacy and safety in these patients. Efficacy (change in seizure frequency/28 days and 50% responder rate) in the elderly subgroup was found to be consistent with the adult population. Adverse event rates were also largely similar, with some exceptions. Because risks of falls, dizziness, and fatigue were greater in the elderly, careful titration of perampanel in patients aged ≥65 years is suggested, especially at higher doses, where balancing tolerability and clinical response is necessary.

Original languageEnglish (US)
Pages (from-to)216-220
Number of pages5
JournalEpilepsy Research
Volume110
DOIs
StatePublished - Feb 1 2015

Bibliographical note

Funding Information:
Editorial support was funded by Eisai Inc. and provided by Imprint Publication Science, New York, NY, USA.

Publisher Copyright:
© 2014 The Authors.

Keywords

  • Adverse effects
  • Antiepileptic drugs
  • Efficacy
  • Elderly
  • Perampanel

Fingerprint

Dive into the research topics of 'Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials'. Together they form a unique fingerprint.

Cite this